Foghorn Net Debt from 2010 to 2025

FHTX Stock

USD 4.31 0.11 2.62%

Foghorn Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -33.3 M in 2025. Net Debt is the total debt of Foghorn Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2010-12-31

Previous Quarter

-31.7 M

Current Value

-33.3 M

Quarterly Volatility

66.9 M

Credit Downgrade

Yuan Drop

Covid

Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.

Check out the analysis of Foghorn Therapeutics Correlation against competitors.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Foghorn Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Foghorn Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Foghorn Net Debt Regression Statistics

	Arithmetic Mean	(46,467,452)
	Coefficient Of Variation	(144.01)
	Mean Deviation	30,977,943
	Median	(32,990,000)
	Standard Deviation	66,916,535
	Sample Variance	4477.8T
	Range	295.9M
	R-Value	(0.23)
	Mean Square Error	4539T
	R-Squared	0.05
	Significance	0.39
	Slope	(3,263,605)
	Total Sum of Squares	67167.3T

Foghorn Net Debt History

	2025	-33.3 M
	2024	-31.7 M
	2023	-35.3 M
	2022	-294.3 M
	2021	-42.8 M
	2020	-10.8 M
	2019	1.6 M

Other Fundumenentals of Foghorn Therapeutics

Net Debt To E B I T D A

Foghorn Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Long Term Debt	Short Term Debt	Net Receivables	Short Term Investments	Capital Surpluse
Total Assets		0.42	0.72	-0.44	-0.83	0.77	0.91	0.93	0.41	1.0	0.99	0.93	0.93	0.53	-0.32	0.99	0.6	0.48	0.78
Total Stockholder Equity	0.42		0.85	-0.11	0.06	-0.08	0.33	0.07	0.99	0.4	0.46	0.34	0.45	0.08	0.33	0.35	0.52	-0.21	-0.18
Net Tangible Assets	0.72	0.85		-0.06	-0.41	0.36	0.69	0.43	0.86	0.69	0.72	0.73	0.8	0.11	-0.08	0.64	0.51	0.02	0.29
Net Debt	-0.44	-0.11	-0.06		0.36	-0.32	-0.32	-0.46	-0.06	-0.44	-0.45	-0.34	-0.29	-0.98	-0.08	-0.46	0.01	-0.82	-0.33
Retained Earnings	-0.83	0.06	-0.41	0.36		-0.95	-0.87	-0.92	0.06	-0.82	-0.77	-0.9	-0.85	-0.49	0.55	-0.82	-0.18	-0.68	-0.93
Accounts Payable	0.77	-0.08	0.36	-0.32	-0.95		0.91	0.88	-0.07	0.75	0.68	0.89	0.84	0.47	-0.45	0.73	0.09	0.68	0.92
Long Term Debt	0.91	0.33	0.69	-0.32	-0.87	0.91		0.88	0.34	0.88	0.85	0.98	0.98	0.46	-0.29	0.85	0.35	0.53	0.8
Total Liab	0.93	0.07	0.43	-0.46	-0.92	0.88	0.88		0.06	0.93	0.9	0.88	0.83	0.57	-0.37	0.93	0.47	0.61	0.92
Net Invested Capital	0.41	0.99	0.86	-0.06	0.06	-0.07	0.34	0.06		0.39	0.45	0.35	0.46	0.05	0.28	0.34	0.49	-0.21	-0.16
Total Current Assets	1.0	0.4	0.69	-0.44	-0.82	0.75	0.88	0.93	0.39		1.0	0.91	0.9	0.53	-0.31	0.99	0.63	0.47	0.78
Net Working Capital	0.99	0.46	0.72	-0.45	-0.77	0.68	0.85	0.9	0.45	1.0		0.88	0.88	0.53	-0.28	0.99	0.68	0.43	0.72
Common Stock	0.93	0.34	0.73	-0.34	-0.9	0.89	0.98	0.88	0.35	0.91	0.88		0.99	0.46	-0.39	0.88	0.34	0.55	0.83
Property Plant Equipment	0.93	0.45	0.8	-0.29	-0.85	0.84	0.98	0.83	0.46	0.9	0.88	0.99		0.42	-0.34	0.87	0.38	0.47	0.76
Current Deferred Revenue	0.53	0.08	0.11	-0.98	-0.49	0.47	0.46	0.57	0.05	0.53	0.53	0.46	0.42		-0.03	0.55	-0.01	0.89	0.45
Short Long Term Debt	-0.32	0.33	-0.08	-0.08	0.55	-0.45	-0.29	-0.37	0.28	-0.31	-0.28	-0.39	-0.34	-0.03		-0.4	0.09	-0.33	-0.62
Short Term Debt	0.99	0.35	0.64	-0.46	-0.82	0.73	0.85	0.93	0.34	0.99	0.99	0.88	0.87	0.55	-0.4		0.63	0.49	0.79
Net Receivables	0.6	0.52	0.51	0.01	-0.18	0.09	0.35	0.47	0.49	0.63	0.68	0.34	0.38	-0.01	0.09	0.63		-0.29	0.2
Short Term Investments	0.48	-0.21	0.02	-0.82	-0.68	0.68	0.53	0.61	-0.21	0.47	0.43	0.55	0.47	0.89	-0.33	0.49	-0.29		0.66
Capital Surpluse	0.78	-0.18	0.29	-0.33	-0.93	0.92	0.8	0.92	-0.16	0.78	0.72	0.83	0.76	0.45	-0.62	0.79	0.2	0.66

Click cells to compare fundamentals

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-31.7 M	-33.3 M
Net Debt To EBITDA	0.30	0.29

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Net Debt from 2010 to 2025

Latest Foghorn Therapeutics' Net Debt Growth Pattern

Foghorn Net Debt Regression Statistics

Foghorn Net Debt History

Other Fundumenentals of Foghorn Therapeutics

Foghorn Therapeutics Net Debt component correlations

About Foghorn Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY